Corneal	B:C0010031
permeation	O
properties	O
of	O
a	O
charged	O
lipid	I:C0023779
nanoparticle	O
carrier	O
containing	O
dexamethasone	O
Drug	O
delivery	I:C0013161
carriers	I:C0013161
can	O
maintain	O
effective	O
therapeutic	O
concentrations	O
in	O
the	O
eye	O
.	O

Corneal	O
permeation	O
properties	O
of	O
a	O
charged	B:C0023779
lipid	I:C0023779
nanoparticle	O
carrier	O
containing	O
dexamethasone	O
Drug	O
delivery	I:C0013161
carriers	I:C0013161
can	O
maintain	O
effective	O
therapeutic	O
concentrations	O
in	O
the	O
eye	O
.	O

Corneal	O
permeation	O
properties	O
of	O
a	O
charged	O
lipid	I:C0023779
nanoparticle	O
carrier	B:C0013161
containing	O
dexamethasone	O
Drug	O
delivery	I:C0013161
carriers	I:C0013161
can	O
maintain	O
effective	O
therapeutic	O
concentrations	O
in	O
the	O
eye	O
.	O

Corneal	O
permeation	O
properties	O
of	O
a	O
charged	O
lipid	I:C0023779
nanoparticle	O
carrier	O
containing	O
dexamethasone	B:C0011777
Drug	O
delivery	I:C0013161
carriers	I:C0013161
can	O
maintain	O
effective	O
therapeutic	O
concentrations	O
in	O
the	O
eye	O
.	O

Corneal	O
permeation	O
properties	O
of	O
a	O
charged	O
lipid	I:C0023779
nanoparticle	O
carrier	O
containing	O
dexamethasone	O
Drug	B:C0013161
delivery	I:C0013161
carriers	I:C0013161
can	O
maintain	O
effective	O
therapeutic	O
concentrations	O
in	O
the	O
eye	O
.	O

Corneal	O
permeation	O
properties	O
of	O
a	O
charged	O
lipid	I:C0023779
nanoparticle	O
carrier	O
containing	O
dexamethasone	O
Drug	O
delivery	I:C0013161
carriers	I:C0013161
can	O
maintain	O
effective	O
therapeutic	O
concentrations	O
in	O
the	O
eye	B:C0015392
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
lipid	B:C0023779
nanoparticles	O
(	O
L	O
/	O
NPs	O
)	O
in	O
which	O
the	O
surface	O
was	O
modified	O
with	O
positively	O
charged	O
chitosan	O
,	O
which	O
engaged	O
in	O
hydrogen	O
bonding	O
with	O
the	O
phospholipid	O
membrane	O
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
lipid	O
nanoparticles	O
(	O
L	B:C0023779
/	O
NPs	O
)	O
in	O
which	O
the	O
surface	O
was	O
modified	O
with	O
positively	O
charged	O
chitosan	O
,	O
which	O
engaged	O
in	O
hydrogen	O
bonding	O
with	O
the	O
phospholipid	O
membrane	O
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
lipid	O
nanoparticles	O
(	O
L	O
/	O
NPs	O
)	O
in	O
which	O
the	O
surface	B:C0205148
was	O
modified	O
with	O
positively	O
charged	O
chitosan	O
,	O
which	O
engaged	O
in	O
hydrogen	O
bonding	O
with	O
the	O
phospholipid	O
membrane	O
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
lipid	O
nanoparticles	O
(	O
L	O
/	O
NPs	O
)	O
in	O
which	O
the	O
surface	O
was	O
modified	O
with	O
positively	O
charged	O
chitosan	B:C0162969
,	O
which	O
engaged	O
in	O
hydrogen	O
bonding	O
with	O
the	O
phospholipid	O
membrane	O
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
lipid	O
nanoparticles	O
(	O
L	O
/	O
NPs	O
)	O
in	O
which	O
the	O
surface	O
was	O
modified	O
with	O
positively	O
charged	O
chitosan	O
,	O
which	O
engaged	O
in	O
hydrogen	O
bonding	O
with	O
the	O
phospholipid	B:C0031676
membrane	O
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
lipid	O
nanoparticles	O
(	O
L	O
/	O
NPs	O
)	O
in	O
which	O
the	O
surface	O
was	O
modified	O
with	O
positively	O
charged	O
chitosan	O
,	O
which	O
engaged	O
in	O
hydrogen	O
bonding	O
with	O
the	O
phospholipid	O
membrane	B:C0005479
.	O

We	O
evaluated	O
in	O
vitro	O
corneal	B:C0010031
permeability	O
and	O
release	O
characteristics	O
,	O
ocular	O
irritation	O
,	O
and	O
drug	O
dynamics	O
of	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
in	O
aqueous	O
humor	I:C0003662
.	O

We	O
evaluated	O
in	O
vitro	O
corneal	O
permeability	O
and	O
release	O
characteristics	O
,	O
ocular	B:C0015392
irritation	O
,	O
and	O
drug	O
dynamics	O
of	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
in	O
aqueous	O
humor	I:C0003662
.	O

We	O
evaluated	O
in	O
vitro	O
corneal	O
permeability	O
and	O
release	O
characteristics	O
,	O
ocular	O
irritation	B:C1706307
,	O
and	O
drug	O
dynamics	O
of	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
in	O
aqueous	O
humor	I:C0003662
.	O

We	O
evaluated	O
in	O
vitro	O
corneal	O
permeability	O
and	O
release	O
characteristics	O
,	O
ocular	O
irritation	O
,	O
and	O
drug	B:C1254351
dynamics	O
of	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
in	O
aqueous	O
humor	I:C0003662
.	O

We	O
evaluated	O
in	O
vitro	O
corneal	O
permeability	O
and	O
release	O
characteristics	O
,	O
ocular	O
irritation	O
,	O
and	O
drug	O
dynamics	O
of	O
modified	O
and	O
unmodified	O
L	B:C0023779
/	O
NPs	O
in	O
aqueous	O
humor	I:C0003662
.	O

We	O
evaluated	O
in	O
vitro	O
corneal	O
permeability	O
and	O
release	O
characteristics	O
,	O
ocular	O
irritation	O
,	O
and	O
drug	O
dynamics	O
of	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
in	O
aqueous	B:C0003662
humor	I:C0003662
.	O

The	O
size	B:C0456389
of	O
L	O
/	O
NPs	O
was	O
uniform	O
and	O
showed	O
a	O
narrow	O
distribution	O
.	O

The	O
size	O
of	O
L	B:C0023779
/	O
NPs	O
was	O
uniform	O
and	O
showed	O
a	O
narrow	O
distribution	O
.	O

The	O
size	O
of	O
L	O
/	O
NPs	O
was	O
uniform	O
and	O
showed	O
a	O
narrow	O
distribution	B:C0037775
.	O

Corneal	B:C0010031
permeation	O
was	O
altered	O
by	O
the	O
presence	O
of	O
chitosan	O
and	O
was	O
dependent	O
on	O
particle	O
size	O
;	O
the	O
apparent	O
permeability	O
coefficient	O
of	O
dexamethasone	O
increased	O
by	O
2.7	O
and	O
1.8	O
times	O
for	O
chitosan	O
-	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
,	O
respectively	O
.	O

Corneal	O
permeation	O
was	O
altered	O
by	O
the	O
presence	B:C0150312
of	O
chitosan	O
and	O
was	O
dependent	O
on	O
particle	O
size	O
;	O
the	O
apparent	O
permeability	O
coefficient	O
of	O
dexamethasone	O
increased	O
by	O
2.7	O
and	O
1.8	O
times	O
for	O
chitosan	O
-	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
,	O
respectively	O
.	O

Corneal	O
permeation	O
was	O
altered	O
by	O
the	O
presence	O
of	O
chitosan	B:C0162969
and	O
was	O
dependent	O
on	O
particle	O
size	O
;	O
the	O
apparent	O
permeability	O
coefficient	O
of	O
dexamethasone	O
increased	O
by	O
2.7	O
and	O
1.8	O
times	O
for	O
chitosan	O
-	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
,	O
respectively	O
.	O

Corneal	O
permeation	O
was	O
altered	O
by	O
the	O
presence	O
of	O
chitosan	O
and	O
was	O
dependent	O
on	O
particle	O
size	O
;	O
the	O
apparent	O
permeability	O
coefficient	O
of	O
dexamethasone	B:C0011777
increased	O
by	O
2.7	O
and	O
1.8	O
times	O
for	O
chitosan	O
-	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
,	O
respectively	O
.	O

Corneal	O
permeation	O
was	O
altered	O
by	O
the	O
presence	O
of	O
chitosan	O
and	O
was	O
dependent	O
on	O
particle	O
size	O
;	O
the	O
apparent	O
permeability	O
coefficient	O
of	O
dexamethasone	O
increased	O
by	O
2.7	O
and	O
1.8	O
times	O
for	O
chitosan	B:C0162969
-	O
modified	O
and	O
unmodified	O
L	O
/	O
NPs	O
,	O
respectively	O
.	O

Corneal	O
permeation	O
was	O
altered	O
by	O
the	O
presence	O
of	O
chitosan	O
and	O
was	O
dependent	O
on	O
particle	O
size	O
;	O
the	O
apparent	O
permeability	O
coefficient	O
of	O
dexamethasone	O
increased	O
by	O
2.7	O
and	O
1.8	O
times	O
for	O
chitosan	O
-	O
modified	O
and	O
unmodified	O
L	B:C0023779
/	O
NPs	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
a	O
chitosan	B:C0162969
-	O
modified	O
system	O
could	O
be	O
a	O
promising	O
method	O
for	O
increasing	O
the	O
ocular	O
bioavailability	O
of	O
unmodified	O
L	O
/	O
NPs	O
by	O
enhancing	O
their	O
retention	O
time	O
and	O
permeation	O
into	O
the	O
cornea	O
.	O

In	O
conclusion	O
,	O
a	O
chitosan	O
-	O
modified	O
system	O
could	O
be	O
a	O
promising	O
method	B:C0025663
for	O
increasing	O
the	O
ocular	O
bioavailability	O
of	O
unmodified	O
L	O
/	O
NPs	O
by	O
enhancing	O
their	O
retention	O
time	O
and	O
permeation	O
into	O
the	O
cornea	O
.	O

In	O
conclusion	O
,	O
a	O
chitosan	O
-	O
modified	O
system	O
could	O
be	O
a	O
promising	O
method	O
for	O
increasing	O
the	O
ocular	B:C0015392
bioavailability	O
of	O
unmodified	O
L	O
/	O
NPs	O
by	O
enhancing	O
their	O
retention	O
time	O
and	O
permeation	O
into	O
the	O
cornea	O
.	O

In	O
conclusion	O
,	O
a	O
chitosan	O
-	O
modified	O
system	O
could	O
be	O
a	O
promising	O
method	O
for	O
increasing	O
the	O
ocular	O
bioavailability	O
of	O
unmodified	O
L	B:C0023779
/	O
NPs	O
by	O
enhancing	O
their	O
retention	O
time	O
and	O
permeation	O
into	O
the	O
cornea	O
.	O

In	O
conclusion	O
,	O
a	O
chitosan	O
-	O
modified	O
system	O
could	O
be	O
a	O
promising	O
method	O
for	O
increasing	O
the	O
ocular	O
bioavailability	O
of	O
unmodified	O
L	O
/	O
NPs	O
by	O
enhancing	O
their	O
retention	O
time	O
and	O
permeation	O
into	O
the	O
cornea	B:C0010031
.	O

These	O
findings	B:C0243095
provide	O
a	O
theoretical	O
basis	O
for	O
the	O
development	O
of	O
effective	O
drug	O
delivery	I:C0085104
systems	I:C0085104
in	O
the	O
treatment	O
of	O
ocular	O
disease	O
.	O

These	O
findings	O
provide	O
a	O
theoretical	O
basis	O
for	O
the	O
development	O
of	O
effective	O
drug	B:C0085104
delivery	I:C0085104
systems	I:C0085104
in	O
the	O
treatment	O
of	O
ocular	O
disease	O
.	O

These	O
findings	O
provide	O
a	O
theoretical	O
basis	O
for	O
the	O
development	O
of	O
effective	O
drug	O
delivery	I:C0085104
systems	I:C0085104
in	O
the	O
treatment	B:C0087111
of	O
ocular	O
disease	O
.	O

